Intratumoral heterogeneity impacts the response to anti-neu antibody therapy. - Wikidata - awgldk - TriplyDB

Intratumoral heterogeneity impacts the response to anti-neu antibody therapy.

Intratumoral heterogeneity impacts the response to anti-neu antibody therapy.

http://www.wikidata.org/entity/Q34169228

about

P1343

The assessment of HER2 status in breast cancer: the past, the present, and the future.A PI3K p110α-selective inhibitor enhances the efficacy of anti-HER2/neu antibody therapy against breast cancer in mice.Clinical significance of intratumor heterogeneity for gynecological carcinoma.

P2860

Q54973346-40684BDC-DD3E-48D3-B05D-C58F0C861E7C

P1343

Q38802932-534002D9-CBF2-4404-8DA3-F49AEA749125 Q54112795-7AF18132-4EEF-47BF-8786-B1D232FB7D14 Q55034894-B3C2D6BC-6619-4B28-A1F9-28FE98865C3C

P2860

Intratumoral heterogeneity impacts the response to anti-neu antibody therapy.

http://www.wikidata.org/entity/Q34169228

description

2014 nî lūn-bûn

@nan

2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Intratumoral heterogeneity impacts the response to anti-neu antibody therapy.

@ast

Intratumoral heterogeneity impacts the response to anti-neu antibody therapy.

@en

Intratumoral heterogeneity impacts the response to anti-neu antibody therapy.

@nl

type

label

Intratumoral heterogeneity impacts the response to anti-neu antibody therapy.

@ast

Intratumoral heterogeneity impacts the response to anti-neu antibody therapy.

@en

Intratumoral heterogeneity impacts the response to anti-neu antibody therapy.

@nl

prefLabel

Intratumoral heterogeneity impacts the response to anti-neu antibody therapy.

@ast

Intratumoral heterogeneity impacts the response to anti-neu antibody therapy.

@en

Intratumoral heterogeneity impacts the response to anti-neu antibody therapy.

@nl

P1433

Q34169228-436000EC-B59C-4AE0-89C6-D7A38650E458

P1476

Q34169228-FE398022-60DE-4100-B06D-CDE8D40C5878

P2093

Q34169228-04331F4A-69D3-47A5-A13A-6F32DD72A1DC

Q34169228-1E77187C-C44F-40CC-A7D6-FEBA4622794E

Q34169228-2C9C8146-9638-41A5-8347-0CF8CE78B003

Q34169228-3DF1CD4D-7A4E-43F5-99BA-B3A67523E414

Q34169228-40193491-B5E4-4845-B43D-D15F881622AD

Q34169228-48766E33-A5BE-47B7-81BA-CD456684C843

Q34169228-75E5ADCD-0141-457E-B656-55F1AE54A1D8

Q34169228-838B4CBE-A125-4463-A04B-FB9AB486C4CD

Q34169228-A2BFCA1C-57F4-4069-8D65-76C8AE7DCB3C

Q34169228-A4F5F959-5C2E-47E7-8CCC-869726F87378

P2860

Q34169228-0F897EE4-04B6-4DBA-8849-A67E2F31154D

Q34169228-1BBCF6D0-5537-42EC-9E25-E5C2CF11EB41

Q34169228-2116D0CB-715D-4AC3-937C-42DE4802A846

Q34169228-24B7BA3D-CDA4-4F44-93FE-5315E14538C4

Q34169228-264D2249-067B-4FC4-872B-F6010289BAB6

Q34169228-2F0C4611-B8BF-4C7E-91F1-E5B2645CF029

Q34169228-4331A410-DEC2-4491-AF82-53E92FDF062F

Q34169228-46A32FA6-A418-42A3-A792-9162CBA12496

Q34169228-47702766-BE20-493F-927F-ECF3990C568C

Q34169228-599DE541-8570-42AB-99E0-A8B7C02D6C5A

P2888

Q34169228-8919A797-B17C-44EB-BF4B-F88A2DB72DF3

P304

Q34169228-FE9D0C17-F1F8-4C6C-AF23-4CFC11D60A3C

P31

Q34169228-8A6BDCFE-1B6F-4046-8F2F-979A0B6C0C5F

P356

Q34169228-F251D484-98B5-46E5-8B31-E88655506BC9

P407

Q34169228-50C39068-50B7-439C-9EA0-4A9B49DB06B8

P433

Q34169228-51CD2317-8420-4810-98A8-07F4AB397E66

P4510

Q34169228-E6D89081-25D9-4D95-8257-3C9A89190F63

P478

Q34169228-5A42F036-D442-4736-A5E7-94632C0386D8

P50

Q34169228-AC292B99-3E84-4A7D-B7C7-7B9E3721D560

P577

Q34169228-0B0718FB-2D34-4112-AAB2-2A1399E582DC

P5875

Q34169228-810C0C01-B619-4CD5-9B87-6E42577311F9

P6179

Q34169228-8CA48E22-9D9D-4BF6-866A-6737EA517D70

P698

Q34169228-126F02CC-8A6C-4D11-B2B7-2833E0BE2C62

P921

Q34169228-F64C0CEB-8660-4D7F-ACF6-09DE36AF3502

P932

Q34169228-DED6ED93-6BA8-447E-9D54-1CA6571E086B

P356

1471-2407-14-647

P1433

P1476

Intratumoral heterogeneity impacts the response to anti-neu antibody therapy

@en

P2093

Eric D Mortenson

http://www.w3.org/2001/XMLSchema#string

Geun Am Song

http://www.w3.org/2001/XMLSchema#string

Hyunkeun Song

http://www.w3.org/2001/XMLSchema#string

Il Whan Choi

http://www.w3.org/2001/XMLSchema#string

Jae-Hyug Choi

http://www.w3.org/2001/XMLSchema#string

Jin-Hee Park

http://www.w3.org/2001/XMLSchema#string

Jin-Ho Kim

http://www.w3.org/2001/XMLSchema#string

Ki Hyaung Kim

http://www.w3.org/2001/XMLSchema#string

Mi Seon Kang

http://www.w3.org/2001/XMLSchema#string

SaeGwang Park

http://www.w3.org/2001/XMLSchema#string

P2860

Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy

Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits

Complex networks orchestrate epithelial-mesenchymal transitions

The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited

Dissemination and growth of cancer cells in metastatic sites

Trastuzumab--mechanism of action and use in clinical practice

EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer

Tumor metastasis: mechanistic insights and clinical challenges

Immune promotion of epithelial-mesenchymal transition and generation of breast cancer stem cells.

ErbB/EGF signaling and EMT in mammary development and breast cancer.

P2888

1471-2407-14-647

P304

647

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-14-647

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P4510

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

265255527

http://www.w3.org/2001/XMLSchema#string

P6179

1050767467

http://www.w3.org/2001/XMLSchema#string

P698

25179116

http://www.w3.org/2001/XMLSchema#string

P921

P932

4161915

http://www.w3.org/2001/XMLSchema#string